Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Bank of America Securities Sticks to Their Sell Rating for Novavax (NVAX)

Tipranks - Tipranks - Sat Nov 8, 2025

In a report released yesterday, Alec Stranahan from Bank of America Securities reiterated a Sell rating on Novavax, with a price target of $7.00. The company’s shares closed yesterday at $7.59.

Meet Your ETF AI Analyst

Stranahan covers the Healthcare sector, focusing on stocks such as Revolution Medicines, Novavax, and Janux Therapeutics Inc. According to TipRanks, Stranahan has an average return of 4.2% and a 56.32% success rate on recommended stocks.

Novavax has an analyst consensus of Hold, with a price target consensus of $11.33.

See Insiders’ Hot Stocks on TipRanks >>

Based on Novavax’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $239.24 million and a net profit of $106.51 million. In comparison, last year the company earned a revenue of $415.48 million and had a net profit of $162.38 million

Read More on NVAX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).